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ARTICLE
Pericyte FAK negatively regulates Gas6/Axl
signalling to suppress tumour angiogenesis
and tumour growth
Tanguy Lechertier1,9, Louise E. Reynolds 1,9, Hyojin Kim2, Ana Rita Pedrosa1, Jesús Gómez-Escudero1,
José M. Muñoz-Félix1, Silvia Batista3, Matthew Dukinfield1, Fevzi Demircioglu1, Ping Pui Wong1,4,
Kylie P. Matchett 5, Neil C. Henderson 5,6, Gabriela D’Amico1, Maddy Parsons 7, Catherine Harwood8,
Pascal Meier2 & Kairbaan M. Hodivala-Dilke 1✉
The overexpression of the protein tyrosine kinase, Focal adhesion kinase (FAK), in endothelial
cells has implicated its requirement in angiogenesis and tumour growth, but how pericyte
FAK regulates tumour angiogenesis is unknown. We show that pericyte FAK regulates
tumour growth and angiogenesis in multiple mouse models of melanoma, lung carcinoma and
pancreatic B-cell insulinoma and provide evidence that loss of pericyte FAK enhances Gas6-
stimulated phosphorylation of the receptor tyrosine kinase, Axl with an upregulation of Cyr61,
driving enhanced tumour growth. We further show that pericyte derived Cyr61 instructs
tumour cells to elevate expression of the proangiogenic/protumourigenic transmembrane
receptor Tissue Factor. Finally, in human melanoma we show that when 50% or more tumour
blood vessels are pericyte-FAK negative, melanoma patients are stratified into those with
increased tumour size, enhanced blood vessel density and metastasis. Overall our data
uncover a previously unknown mechanism of tumour growth by pericytes that is controlled
by pericyte FAK.
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Pericytes are perivascular cells whose role, via interactionsand crosstalk with endothelial cells (ECs)1–3, in physiolo-gical angiogenesis is well established. However, the mole-
cular mechanisms involved in the regulation of tumour growth,
by pericytes is still unknown. It is accepted that, in tumours, a
mis-regulation of endothelial cell–pericyte interactions and
crosstalk leads to instability of the microvasculature4,5 that can
regulate tumour growth, progression, and metastasis6,7. More
recently, growing evidence supports a new role for cross-talk
between pericytes and tumour cells8,9.
The protein tyrosine kinase, focal adhesion kinase (FAK) is
upregulated in many cancer types leading to the development of
FAK-inhibitors that are currently in clinical trials10. Unfortu-
nately, monotherapy with FAK-inhibitors shows no overall ben-
efit and raises the question of the precise regulation of tumour
growth by FAK in various cell types of the tumour. FAK is
thought to regulate adhesion, proliferation, migration, and sur-
vival of ECs11 and the role of FAK in angiogenesis has been
studied using EC FAK knockout animal models12–14. Further
work has shown the requirement of EC FAK in the initiation of
tumour angiogenesis15,16. However, the role of pericyte FAK in
tumourigenesis has never been investigated.
Here we identify pericyte FAK as a negative regulator of
tumour angiogenesis and tumour growth, through its control of
Gas6-stimulated Axl activation. Furthermore, we have identified
the relationship between pericyte FAK expression on blood ves-
sels and tumour angiogenesis and growth in human melanoma
samples. Together, these data highlight an important role for
cross-talk between pericytes, ECs and tumour cells, rather than
with ECs alone, in the regulation of tumour angiogenesis and
growth and place pericyte FAK as an important regulator in this
process.
Results
Pericyte FAK deficiency increases tumour growth and tumour
angiogenesis. The role of pericyte FAK in tumour growth is
unknown. To develop a genetic tool to assess how loss of pericyte
FAK could affect tumour growth, we used Cre-lox recombination
to delete FAK in pdgfrβcre+ cells. Pdgfrβcre-;fakfl/fl and pdgfrβcre
+;fakfl/fl mice were born at normal Mendelian ratios, and
showed no defects in weight, gender distribution or large vessel
morphology in unchallenged tissue (Supplementary Fig. 1a–d).
FAK expression was not affected in endothelial cells or fibroblasts
from pdgfrβcre+;fakfl/fl mice but was specifically deleted in
pericytes isolated from pdgfrβcre+;fakfl/fl mice, at both protein
and RNA levels, with no change in Pdgfrβ RNA levels (Supple-
mentary Fig. 1e, f).
To examine the effect of pericyte FAK loss on tumour growth
and angiogenesis, pdgfrβcre+;fakfl/fl and pdgfrβcre-;fakfl/fl mice
were injected subcutaneously with either B16F0 melanoma or
Lewis lung carcinoma (LLC) cells. In both models, tumours grew
significantly bigger in pdgfrβcre+;fakfl/fl animals when compared
with the pdgfrβcre-;fakfl/fl controls (Fig. 1a). To extend
these effects to a spontaneous tumour model we crossed the
pdgfrβcre+;fakfl/fl mice with RIP-Tag mice, a model of pancreatic
insulinoma17. At 15 weeks of age, RIP-Tag;pdgfrβcre+;fakfl/fl
mice displayed larger tumours than RIP-Tag; pdgfrβcre-;fakfl/fl
controls, suggesting that the loss of pericyte FAK was also
sufficient to control tumour growth in this spontaneous model of
cancer (Fig. 1b). This increase in tumour growth in pdgfrβcre+;
fakfl/fl mice correlated with enhanced tumour blood vessel
density (Fig. 1c) that was not apparent in unchallenged skin
(Supplementary Fig. 1g). Importantly, in tumour burdened
pdgfrβcre+;mTmG reporter mice, the specificity of Cre expression
in pericytes associated with tumour blood vessels was confirmed.
In detail, blood vessels from pdgfrβcre-;mTmG and pdgfrβcre+;
mTmG mice both displayed tomato (mT) signal in host cells, but
after Cre excision GFP (mG) was only observed in pdgfrβcre+;
mTmG mouse tumour pericytes (Supplementary Fig. 1h). When
examining unchallenged skin TdTom; pdgfrβcre- mice had no
apparent TdTom signal (data not shown). Importantly, immuno-
fluorescence staining for Pdgfrβ showed a weak signal in 76% of
dermal vessels indicating that Pdgfrβ is poorly expressed in
pericytes of unchallenged adult mouse skin. Furthermore,
TdTomato (TdTom) signal in TdTom; pdgfrβcre+ mice, showed
TdTom in approximately 36% of dermal vessels. This result
indicated poor pdgfrβ-cre activity in mural cells of dermal blood
vessels (Supplementary Fig. 1i) likely explaining the lack of a
blood vessel phenotype in unchallenged skin of pdgfrβcre+;fakfl/fl
mice. Immunostaining for FAK confirmed in vivo pericyte-FAK
loss in tumours from pdgfrβcre+;fakfl/fl mice (Supplementary
Fig. 1j). These data validated that pdgfrβ-driven FAK deletion
in vivo is restricted to tumour pericytes in the experimental
settings used.
Given that FAK plays a role in cell migration and adhesion, it
was not necessarily surprising that pericyte FAK deficiency
reduced significantly the association of NG2-positive and α-SMA-
positive (that were also shown to be Pdgfrβ-positive) pericytes
with tumour blood vessels (Fig. 1d, Supplementary Figs. 2 and 3).
Despite this, there was no increase in blood vessel leakage in
tumours from these mice when compared with control mice
(Fig. 1e). Severe loss of pericyte association with blood vessels has
been reported to affect microvessel dilation, basement membrane
deposition and perfusion18,19. Histological examination of the
tumour blood vessels showed no effect on microvessel dilation,
laminin deposition, VE-cadherin localisation (Supplementary
Fig. 4a–c) or perfusion between the genotypes (Supplementary
Fig. 5). This suggests that decreased pericyte investment of blood
vessels in pdgfrβcre+;fakfl/flmouse tumours does not affect blood
vessel leakage or perfusion. In line with the enhanced tumour
angiogenesis observed in Fig. 1c, endothelial cell proliferation was
increased significantly in B16F0 tumours grown in pdgfrβcre+;
fakfl/fl mice when compared with control mice (Fig. 1f). Given
the pro-angiogenic phenotype in the pdgfrβcre+;fakfl/fl mice, we
next examined the effect on tumour immune cell infiltration,
especially since F4/80+ macrophages are thought to control
angiogenesis20. No apparent defect in CD45+ or F4/80+ immune
cell infiltration was observed in subcutaneous or RIP-Tag
tumours grown in pdgfrβcre+;fakfl/fl mice, suggesting that
immune cell infiltration was not a major factor in tumour growth
control (Supplementary Fig. 6). In short, loss of pericyte FAK, in
contrast to the loss of endothelial FAK16, was sufficient to
enhance tumour growth and angiogenesis in three models of
cancer with a reduction in pericyte-microvessel association.
Determining the molecular players in the enhanced tumour
angiogenesis in pdgfrβcre+;fakfl/fl mice. To determine which
growth factors may be responsible for the enhanced tumour
angiogenesis in pdgfrβcre+;fakfl/fl mice, synthetic sponges were
implanted subcutaneously into pdgfrβcre-;fakfl/fl and pdgfrβcre+;
fakfl/fl mice, and angiogenesis was stimulated with PBS (control),
PDGF-B, PlGF, or VEGF. Interestingly, although no differences
in PBS-stimulated angiogenesis were observed between geno-
types, we did not see an increase in blood vessel density in
response to PDGF-B, PlGF, and VEGF, but rather a decrease
(Fig. 2a). This was despite a significant decrease in pericyte
coverage of blood vessels in growth factor induced angiogenesis
in pdgfrβcre+;fakfl/fl mice, as determined by α-SMA immunos-
taining, a known marker for pericytes (Fig. 2b). In vitro, random
cell migration in response to serum was enhanced in WT
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pericytes but not FAK-null pericytes, suggesting that the absence
of FAK abrogates serum dependent migration speed (Fig. 2c). At
a cellular level, despite the loss of FAK, pericytes showed no
defect in adhesion to various matrices including fibronectin,
collagen I, collagen IV, laminin 1 or fibrinogen (Fig. 2d) and also
showed no defect in cellular proliferation (Fig. 2e) or expression
of other focal contact proteins including vinculin, talin, paxillin
and phospho-paxillin (Supplementary Fig. 7a). Since PDGF-B
stimulation enhances pericyte migration and proliferation
through activation of PDGFRβ, we examined PDGF-B stimulated
signalling in WT and FAKKO pericytes. Levels of PDGFRβ, p-
PDGFRβ, ERK1/2 and p-ERK1/2, AKT and p-AKT, JNK/SAPK
and p-JNK/SAPK were similar between the two genotypes
(Fig. 2f). Although FAK deletion was not apparent in endothelial
cells isolated from pdgfrβcre+;fakfl/fl mice, since our in vivo
results showed that endothelial cell proliferation was enhanced in
tumours grown in these mice, we examined VEGF-receptor 2
(VEGFR2) levels and downstream ERK1/2 phosphorylation in
endothelial cells isolated from pdgfrβcre-;fakfl/fl and pdgfrβcre+;
fakfl/fl mice. There were no differences in VEGF-stimulated
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p-VEGFR2:VEGFR2 or p-ERK1/2:ERK1/2 levels between the
endothelial cells from pdgfrβcre-;fakfl/fl or pdgfrβcre+;fakfl/fl
mice or between endothelial cells stimulated with PlGF, indicat-
ing that the enhanced endothelial cell proliferation in tumours
grown in pdgfrβcre+;fakfl/fl mice was due to secondary effects of
pericyte FAK-deficiency (Fig. 2g). These results show that dele-
tion of pericyte FAK does not affect PDGF-B mediated-signalling
and that ECs from pdgfrβcre-;fakfl/fl and pdgfrβcre+;fakfl/fl mice
are not intrinsically affected either after VEGF, or PlGF, stimu-
lation. Together, these data suggest that other pro-angiogenic
factors apart from VEGF, PDGF-B and PlGF are involved in the
enhanced tumourigenesis in pdgfrβcre+;fakfl/fl mice.
Exogenous Gas6 enhances angiogenic responses via pericyte
Axl in FAKKO pericytes. In addition to VEGF, PDGF-B and
PlGF, Gas6 is also highly upregulated in cancer cells. Gas6 can be
expressed at nanomolar levels, and is thought to have proangio-
genic functions, but the regulation of Gas6-mediated angiogenesis
remains relatively obscure21,22. In ex vivo assays, stimulation with
recombinant Gas6 (100 ng), but not PBS, enhanced sprouting
angiogenesis in aortic rings from pdgfrβcre+;fakfl/fl mice com-
pared with pdgfrβcre-;fakfl/fl mice (Fig. 3a). These data suggested
that exogenous Gas6 stimulated responses are elevated by the
loss of pericyte FAK. Moreover, CRIPSR-Cas 9 depletion of
Gas6 in B16 cells reduced the enhanced tumour growth in
pdgfrβcre+;fakfl/flmice, but had no significant effect in pdgfrβcre-
;fakfl/fl mice, indicating that tumour cell derived Gas6 is involved
in the enhanced tumour responses in pdgfrβcre+;fakfl/fl mice
(Fig. 3b).
In line with these results, Protein profiler array analysis
identified phospho-Axl (p-Axl), a member of the TAM (Tyro3,
Axl and Mer) family of receptor tyrosine kinases and the major
receptor for Gas6, as the most significantly upregulated phospho-
receptor tyrosine kinase in FAKKO pericytes when compared with
WT pericytes, despite no change in transcript levels of Axl
(Fig. 3c). These results suggested that constitutively elevated p-
Axl in FAKKO pericytes could be responsible for priming these
cells to be hyper-responsive to exogenous Gas6. Indeed, western
blot analysis confirmed that FAKKO pericytes had significantly
increased p-Axl levels which were maintained after Gas6 (100 ng/
ml) stimulation up to 10 min after stimulation (Fig. 3d). The
binding affinity of Axl to Gas6 has been reported to be
significantly higher than for Tyro323, and although p-Tyro3
levels were also increased in FAKKO pericytes (Supplementary
Fig. 7b) we focused on pericyte Axl as the major Gas6 receptor in
the enhanced Gas6-stimulated angiogenic responses controlled by
pericyte FAK.
To test the functional requirement of pericyte Axl in the
enhanced tumour growth and angiogenesis regulated by FAK, Axl
was depleted by CRISPR-Cas9 gene editing in FAKKO pericytes
(FAK-null;AxlKO pericytes). In vivo, the effect of targeting Axl in
FAKKO pericytes was tested by co-injecting wildtype C57bl6 mice
with B16F0 tumour cells and either FAK-null;AxlKO, FAK-null;
Cas9 or WT;Cas9 control pericytes. Depletion of Axl in FAKKO
pericytes reduced the enhanced tumour growth and angiogenesis
observed in mice co-injected with FAK-null;Cas9 pericytes
(Fig. 3e) suggesting that the elevated p-Axl in FAKKO pericytes
is likely involved in the enhanced tumour growth in pdgfrβcre+;
fakfl/fl mice.
A previously published study indicated that Axl cross-
regulates Gas6 expression in the same cell type and that this co-
regulation of endogenous Axl and Gas6 is important in
subsequent downstream signalling24. Supporting this and
correlating with the enhanced p-Axl expression levels observed
in FAKKO pericytes, Gas6 expression was increased signifi-
cantly (high picomolar levels) in FAKKO pericytes compared
with WT pericyte controls. Additionally, pericyte Gas6 expres-
sion levels were reduced by Axl-depletion in FAKKO pericytes
(Fig. 3f). Conversely, Gas6-depletion in FAKKO pericytes also
resulted in a significant reduction in p-Axl in FAK-null;Gas6KO
pericytes, measured by p-Axl staining intensity (Fig. 3g).
Together these data suggest that Axl and Gas6 cross regulate
their expression levels in pericytes. In vivo, the loss of Gas6 in
FAKKO pericytes also reduced tumour size and angiogenesis in
mice co-injected with FAK-null;Gas6KO and B16F0 tumour
cells compared with mice co-injected with FAK-null;Cas9
pericytes and B16 tumour cells (Fig. 3h). Thus, together these
data suggest that in the absence of exogenous Gas6, pericyte-
derived Gas6 is not sufficient to affect angiogenesis and this is
illustrated by the ex vivo assays in Fig. 3a. However, in vivo,
tumour derived Gas 6 responses are enhanced, due to elevated
Axl/Gas6-signallling in FAKKO pericytes, and this response
results in the enhanced tumour growth in pdgfrβcre+;fakfl/
fl mice.
Whilst loss of FAK has been shown to correlate with
compensation by its family member Pyk225, cross-regulation of
Gas6/Axl with Pyk2 and FAK, but not Src, have been reported
previously in cancer cells26. Corroborating these results, Western
blot analysis showed that p-Pyk2 was elevated in FAKKO
pericytes with no apparent effect on p-Src (Fig. 3i). Using PF-
562,271, a FAK/Pyk2 dual kinase inhibitor, we showed that in
Fig. 1 Tumour growth and angiogenesis are enhanced in pdgfrβcre+;fakfl/fl mice. a B16F0 melanoma and Lewis Lung Carcinoma (LLC) subcutaneous
tumour growth was increased in pdgfrβcre+;fakfl/fl mice compared with pdgfrβcre-;fakfl/fl mice. Images of representative tumours. Data show mean ±
s.e.m. n= 17 (B16F0) and 7 (LLC) pdgfrβcre-;fakfl/fl and 25 (B16F0) and 8 (LLC) pdgfrβcre+;fakfl/fl mice per tumour type. **p= 0.009. Scale bar, 500 μm.
b Spontaneous pancreatic insulinoma tumour volume is increased in RIP-Tag;pdgfrβcre+;fakfl/fl mice compared with RIP-Tag;pdgfrβcre-;fakfl/fl mice.
Chart represents mean total macroscopic tumour volume ± s.e.m. n= 9 RIP-Tag;pdgfrβcre-;fakfl/fl and 11 RIP-Tag;pdgfrβcre+;fakfl/fl mice. **p= 0.0042.
Representative images of pancreatic tumours stained for SV40. Scale bar, 0.5 cm. c Tumour blood vessel density is increased in tumours grown in
pdgfrβcre+;fakfl/fl compared with pdgfrβcre-;fakfl/fl mice. Charts represent mean ± s.e.m. n= 3 pdgfrβcre-;fakfl/fl and 3 pdgfrβcre+;fakfl/fl B16F0 tumours,
**p= 0.009; 19 pdgfrβcre-;fakfl/fl and 12 pdgfrβcre+;fakfl/fl LLC tumours *p= 0.0207; 7 RIP-Tag;pdgfrβcre-;fakfl/f and 10 RIP-Tag;pdgfrβcre+;fakfl/fl
tumours, **p= 0.0097. Representative images of endomucin stained sections. Scale bar for B16F0 and LLC tumour sections, 200 µm. Scale bar for RIP-Tag
tumour sections, 300 µm. d Pericyte association with tumour blood vessels is reduced in pdgfrβcre+;fakfl/fl and RIP-Tag;pdgfrβcre+;fakfl/fl mice. Charts
represent the percentage of α-SMA positive blood vessels ± s.e.m. n= 5 pdgfrβcre-;fakfl/fl, 6 pdgfrβcre+;fakfl/fl, 10 RIP-Tag;pdgfrβcre-;fakfl/fl, 9 RIP-Tag;
pdgfrβcre+;fakfl/flmouse tumours. **p= 0.0043 (B16F0), **p= 0.003 (RIP-Tag). e Blood vessel leakage was similar in tumours from pdgfrβcre-;fakfl/fl and
pdgfrβcre+;fakfl/fl mice. Chart shows Hoechst area relative to blood vessel area ± s.e.m. n= 25 high power fields in tumours from 4 pdgfrβcre-;fakfl/fl mice
and 34 fields in tumours from 4 pdgfrβcre+;fakfl/fl mice. f Blood vessel associated endothelial cells from pdgfrβcre+;fakfl/fl mice have increased
proliferation. Lower panels show representative high power images of insert Ki67, DAPI, endomucin. Chart represents the percentage of proliferating
endothelial cells per area ± s.e.m., n= 24 and 27 fields in 4 pdgfrβcre-;fakfl/fl, 5 pdgfrβcre+;fakfl/fl mouse tumours respectively. *p= 0.0457. a–e two-sided
Mann–Whitney U-test; c, d, f Two-sided Student’s t-test; ns not significant. Source data are provided as a Source data file.
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WT pericytes inhibition of FAK/Pyk2 led to increased Gas6 levels.
Inhibition of Pyk2 in FAKKO pericytes, however, caused a
significant reduction in pericyte Gas6 transcript levels, suggesting
a putative mechanism by which loss of pericyte FAK is
compensated by elevated p-Pyk2 in the regulation of endogenous
Gas6/Axl (Fig. 3j). These results show (i) that FAK regulates Gas6
levels and (ii) kinase inhibition can partially mimic the effect of
genetic ablation of FAK.
Exogenous Gas6 stimulates angiogenesis by elevating Cyr61 in
FAKKO pericytes. The molecular regulation induced by exogenous
a
b
c d e
gf
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16618-6 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:2810 | https://doi.org/10.1038/s41467-020-16618-6 |www.nature.com/naturecommunications 5
Gas6-stimulation was further explored in order to identify the
precise factor(s) that control the enhanced angiogenesis when
pericyte FAK is deleted. In unstimulated conditions no apparent
changes in angiogenesis modulators, including Vegf-receptor 2
were observed in FAKKO vs. WT pericytes (Supplementary
Fig. 8a, b) supporting the idea that exogenous stimulation was
required for the observed upregulation of angiogenesis. Of note,
endothelial cells from pdgfrβcre+;fakfl/fl and pdgfrβcre-;fakfl/fl
mice showed no change in p-Axl levels and had no detectable
levels of Tyro3 also reinforcing the hypothesis that pericyte FAK
loss did not constitutively affect endothelial cells in the absence of
exogenous stimulation (Supplementary Fig. 8c). However, stimu-
lation of pericytes by co-culture with B16F0 cells upregulated the
expression of several pro-angiogenic proteins, including Cyr61, in
FAKKO pericytes compared with WT pericytes (Fig. 4a and Sup-
plementary Fig. 9a). Indeed, exogenous Gas6 stimulation (100 nM)
enhanced Cyr61 expression in FAKKO but not WT pericytes and
this increase in Cyr61 expression was abolished by deletion of Axl
in FAKKO pericytes (Fig. 4b). Together these results indicated that
the increased levels of Gas6 expression in FAKKO pericytes are not
sufficient to stimulate Cyr61 expression and that exogenous sti-
mulation is required.
Cyr61 is known to be involved in regulating cell proliferation
through interaction with integrins expressed on endothelial cells
and tumour cells27–30. Endothelial spheroid sprouting assays
corroborated that stimulation with recombinant Cyr61 is
proangiogenic (Fig. 4c). To test the requirement for pericyte
Cyr61 in tumour growth FAK-null;Cyr61KO pericytes were
generated by CRIPSR-Cas9 gene editing (Fig. 4d). Co-injection
of B16F0 cells with FAK-null;Cyr61KO pericytes into wild type
mice reduced significantly the enhanced tumour growth and
angiogenesis observed after co-injection of B16F0 cells with FAK-
null;Cas9 control pericytes (Fig. 4e). Cyr61 deletion in
FAKKO pericytes also had no effect on endogenous, pericyte
Gas6 expression levels placing pericyte Gas6 up-stream of Cyr61
(Supplementary Fig. 9b). These data established that the elevated
expression of Cyr61, downstream of pericyte Gas6/Axl, in FAKKO
pericytes is involved in the regulation of angiogenesis and tumour
growth in vivo.
Signalling downstream of Axl is known to be mediated via
multiple signalling pathways including PI3K/Akt/mTOR, MEK/
ERK and NF-KB pathways31,32. Our data show that whilst
exogenous Gas6-stimulation enhanced both p-Akt and p-p65
NFkB expression (Fig. 4f and Supplementary Fig. 10a, respec-
tively), depletion of pericyte Gas6 or Axl in FAKKO pericytes
reduced p-AKT/AKT levels dramatically (Supplementary
Fig. 10b) demonstrating that the enhanced AKT activation in
exogenous Gas6-stimulated FAKKO pericytes requires pericyte
Gas6 and Axl.
Despite this observation, co-injection of FAK-null;AKTKO
pericytes (Supplementary Fig. 10c) with B16F0 tumour cells did
not affect the enhanced tumour growth or angiogenesis compared
with co-injection of FAK-null;Cas9 pericytes with B16F0 tumour
cells (Supplementary Fig. 10d, e). However, previously published
studies have indicated that genetic deletion of AKT can induce
compensation by multiple alternative pathways overcoming the
loss of AKT and our data suggest that this may be a limitation of
this approach in understanding the relevance of pericyte AKT
in vivo. As an alternative, we inhibited AKT in WT and FAKKO
pericytes using the PI3-kinase inhibitor GDC-0941 and stimu-
lated or not with Gas6. AKT inhibition in the absence of Gas6 did
not affect Cyr61 levels compared with basal conditions, implying
that despite the increased in basal p-AKT observed in FAKKO
pericytes, it is not enough to stimulate Cyr61. However, in
FAKKO pericytes, the addition of exogenous Gas6 and AKT
inhibition did significantly reduce Cyr61, which was not observed
in WT pericytes, implying a requirement for exogenous Gas6 in
the regulation of Cyr61through AKT (Fig. 4g).
In addition to the effect of Cyr61 on endothelial cells in
regulating angiogenic responses, previous reports have indicated
that Cyr61 directly affects tumour cells promoting cancer cell
invasion and overexpression of Cyr61 enhances tumour
growth33–35. Thus, we next examined the mechanism(s) by
which pericyte signals could affect tumour cells directly. Co-
culture of FAKKO pericytes with B16F0 cells enhanced expression
of B16F0 coagulation factor III/tissue factor (TF), and, more
modestly, Serpin E1 compared with B16F0 cells after co-culture
with WT pericytes (Fig. 4h and Supplementary Fig. 11). TF is a
pleotropic factor that is involved in accelerating tumour growth
and further enhancing angiogenesis36. Serpin E1 is a secreted
protein and regulator of urokinase and tissue-type plasminogen
activators. It is involved in the promotion of invasion by
degradation of extracellular matrix and activation of matrix
metalloproteinase37. Increased tissue expression of Serpin E1 in
stomach and lung cancer correlates with poor prognosis38. B16F0
tumour cell stimulation with Cyr61 enhanced tumour cell TF
expression, suggesting that the elevated Cyr61 produced by
FAKKO pericytes may be sufficient to directly affect tumour cell
TF expression (Fig. 4i). To determine the contribution of B16F0
TF to tumour growth, TF was depleted in B16 cells and these cells
(B16;TFKO) injected into pdgfrβcre+;fakfl/fl and pdgfrβcre-;fakfl/
flmice. Depletion of TF in B16F0 cells was sufficient to reduce the
enhanced tumour growth in pdgfrβcre+;fakfl/fl and had no effect
on tumour growth in pdgfrβcre-;fakfl/fl mice (Fig. 4j). Together
Fig. 2 FAK deletion in pericytes inhibits angiogenesis in response to VEGF, PDGF-B and PlGF. a VEGF-stimulated, PDGF-B-stimulated and PlGF-
stimulated angiogenesis in vivo were all reduced significantly in pdgfrβcre+;fakfl/fl mice. Charts represent quantitation of blood vessels in infiltrated areas
of sponges ± s.e.m., n= 7 and 9 PBS and 7 and 8 VEGF treated sponges in pdgfrβcre-;fakfl/fl and pdgfrβcre+;fakfl/fl mice, respectively. 9 and 7 PDGF-B and
8 and 8 PlGF treated sponges in pdgfrβcre-;fakfl/fl and pdgfrβcre+;fakfl/flmice, respectively; ***p= 0.0002 (VEGF), **p= 0.0019 (PDGF-B), ****p < 0.0001
(PlGF). Representative images of endomucin stained sections of sponges. Scale bar, 100 μm. b α-SMA-positive pericyte association with blood vessels
were reduced in sponges from pdgfrβcre+;fakfl/fl mice when compared with pdgfrβcre-;fakfl/fl mice. Charts represent percentage of α-SMA-positive blood
vessels ± s.e.m., n= 5 sponges each from pdgfrβcre-;fakfl/fl and pdgfrβcre+;fakfl/fl mice, ***p= 0.0004. Representative images of α-SMA/endomucin
stained sections of sponges. Scale bar, 200 μm. c FAKKO pericyte migration speed is decreased in response to serum. Chart represents migration speed in
serum starved WT and FAKKO pericytes and WT and FAKKO pericytes in the presence of serum + s.e.m. **p < 0.005, *p < 0.01, n= 3 biological repeats in
duplicate. d WT and FAKKO pericytes showed no difference in adhesion to BSA, Fibronectin, Collagen I, Collagen IV, Laminin 1 or Fibrinogen. Chart
represents the relative number of cells that attached to the matrix normalised to BSA (negative control) ± s.e.m. n= 8 replicates. e WT and FAKKO
pericytes proliferate at a similar rate. Line graph represents mean ± s.e.m.; n= 4 wells/genotype, 5 experimental repeats. f WT and FAKKO pericytes show
no differences in signalling in response to PDGF-B. Graphs represent the densitometric quantitation of p-ERK1/2/ERK1/2 ratio, p-AKT:AKT ratio and p-JNK:
JNK ratio ± s.e.m.; n= 2 experimental repeats. g Endothelial cells isolated from pdgfrβcre-;fakfl/fl and pdgfrβcre+;fakfl/fl show no differences in signalling in
response to VEGF or PlGF. Graphs represent the densitometric quantitation of p-VEGFR2/VEGFR2 with VEGF, p-ERK/ERK with VEGF and p-ERK/ERK with
PlGF ratios ± s.e.m.; n= 3 experimental repeats. a–c Two-sided Students t-test, ns not significant. Source data are provided as a Source data file.
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these data demonstrate that Cyr61 stimulation from FAK-null
pericytes is sufficient to enhance B16F0 TF expression and that
deletion of B16F0 TF can rescue the enhanced tumour growth in
pdgfrβcre+;fakfl/fl mice.
Reduced expression of pericyte FAK is associated with human
melanoma progression. Finally, we established that pericyte FAK
loss was relevant to human melanoma progression. Primary
human cutaneous melanoma sections were double immunos-
tained for the pericytes and FAK to determine levels of pericyte
FAK, and the percentage of blood vessels in which pericyte FAK
was not detectable was established. Results revealed that pericyte
FAK was detected only on a sub-set of blood vessels (Fig. 5a). The
percentage of pericyte FAK undetectable blood vessels ranged
between 11 and 100% across individual patient samples (Fig. 5b).
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Similar to our mouse data, we showed that a high proportion of
pericyte FAK-undetectable blood vessels (i.e., when more than
50% of the vessels are pericyte FAK-undetectable) stratifies
patients into those with increased blood vessel density (Fig. 5c),
enhanced tumour burden (identified by increasing Breslow
thickness) (Fig. 5d) and increased metastasis (Fig. 5e). Together
these data indicate that a high percentage of blood vessels where
pericyte FAK is undetectable is associated with enhanced tumour
size and progression in human melanoma, and implies that
pericyte FAK expression is protective in human cancer.
In summary, loss of pericyte FAK is compensated by an
increase in pericyte p-Pyk2 which enhances pericyte p-Axl and
concomitantly pericyte Gas6 expression. This primes FAKKO
pericytes to be more responsive to exogenous Gas6, derived from
tumour cells, driving sustained activation of pericyte AKT and
enhanced Cyr61 expression. This pericyte-derived Cyr61 is
sufficient to enhance tumour growth and angiogenesis whilst
also promoting TF expression perpetuating the accelerated
tumour growth and angiogenesis in vivo (Fig. 5f).
Discussion
In contrast to previous studies in which FAK was deleted in ECs
and resulted in a reduction in tumour growth in multiple mouse
models of cancer15,16,39,40 our results demonstrate that loss of
pericyte FAK enhances tumour growth and tumour angiogenesis.
Previously, pericytes have been shown to play critical roles in vas-
cular development, the control of vessel contraction, blood flow and
haemostasis1,41 but their roles beyond this are poorly defined.
Indeed, although pericyte FAK loss reduces pericyte-blood-vessel
association this is not sufficient to explain the enhanced tumour
angiogenesis and growth in pdgfrβcre+;fakfl/fl mice.
Gas6 and Axl, known to co-regulate their expression, are
expressed in pericytes24 and upregulated in many human can-
cers21,22,42,43, but the role of Axl signalling during angiogenesis in
pericytes was unknown. Overall our study identifies that pericyte
FAK expression protects against enhanced tumour growth via the
regulation of pericyte Gas6-Axl-AKT-signalling pathway and
subsequent control of Cyr61. Cyr61 is largely secreted by peri-
cytes44,45 and is implicated in tumour growth and angiogen-
esis29,33,39,46 through stimulating EC proliferation/migration28.
Thus, the overexpression of pericyte Cyr61 in FAKKO pericytes is
likely to be part of the mechanism by which loss of pericyte FAK
can enhance tumour angiogenesis. Additionally, since we showed
that Cyr61 can upregulate TF expression in tumour cells, and TF
is known to drive tumour growth47, our data reveal a parallel
mechanism by which pericyte regulation of Cyr61 and sub-
sequent tumour cell TF drives accelerated tumour growth in the
absence of pericyte FAK in vivo. This establishes a new molecular
mechanism whereby pericyte-tumour cell cross-talk in addition
to pericyte-endothelial cell cross-talk could control tumour
angiogenesis and tumour growth.
Interestingly, FAK kinase inhibition, using PF-271, also par-
tially mimics pericyte FAK deletion but the clinical impact of this
result if currently unknown.
Our data emphasise that FAK has pleotropic roles in the reg-
ulation of cancer and angiogenesis in both preclinical models and
clinical samples.
Methods
Mice. Floxed FAK mice (FAKfl/fl) with two LoxP sites flanking the exon that
encodes FAK amino acids 413–444 were crossed with mice that express Cre
recombinase under the control of the platelet derived growth factor receptor ß
(pdgfrß) promoter to generate pdgfrβcre+;fakfl/fl and pdgfrβcre−;fakfl/fl mice.
pdgfrβcr+/−;fakfl/fl mice were crossed with RIP-Tag2 mice generating RIP-Tag;
pdgfrß cre-;FAKfl/fl and RIP-Tag;pdgfrß cre+;FAKfl/fl mice. For animals bred in-
house, health screens (quarterly) were conducted in accordance with FELASA
guidelines for health monitoring of rodent colonies, to confirm their free status of
known pathogens in accordance with FELASA screens. No clinical signs were
detected. Animals were housed in groups of 4–6 mice per individually ventilated
cage in a 12 h light dark cycle (06:30–18:30 light; 18:30–06:30 dark), with controlled
temperature (21 ± 1 °C) and relative humidity (40–60%). The cages contained
1–1.5 cm layer of animal bedding, and with environmental enrichment including
cardboard box-tunnel and crinkled paper nesting material. Animals had access to
food and water ad libitum. All mice were maintained on a mixed C57/Bl6J/129
background. Both male and female mice were used, between 8 and 10 weeks of age,
for all experiments.
In vivo tumour growth. Age- and sex-matched pdgfrcreß+;fakfl/fl and wild-type
littermate controls (pdgfrcreß-;fakfl/fl) were given a single subcutaneous injection
into the flank of either 1 × 106 B16F0 melanoma cells or 0.5 × 106 Lewis lung
carcinoma cells (ATCC). Tumour dimensions were measured over time and
tumour growth was determined using the formula: length × width2 × 0.52. When
tumours reached the maximum legal size allowed, mice were killed, tumour sizes
measured and tumour samples were either snap-frozen or fixed in 4% paraf-
ormaldehyde (PFA) for histological analysis. RIP-Tag;pdgfrßcre-;fakfl/fl and RIP-
Tag;pdgfrßcre+;fakfl/fl mice were killed and tumours harvested at 15 weeks. The
total macroscopic tumour volume was measured. Tumours were harvested and
fixed in 4% PFA for histological analysis. Blood vessel density was assessed by
counting the total number of endomucin (V.7C7, sc-65495, Santa Cruz, 1:100)
stained blood vessels per mm2 across entire midline tumour sections of size- and
age-matched B16F0, LLC and Rip-Tag pancreatic tumours. To examine tumour
blood vessel leakage, an intravenous injection of Hoechst (100 µl at 4 mg/ml)
(14533, Sigma) was given 1 min before mice were killed. ImageJTMsoftware was
used to quantify the Hoechst positive area per optical field and leakage was
Fig. 3 Exogenous Gas6 enhances angiogenic responses in FAKKO pericytes. a Aortic vessel sprouting quantitation. Graphs mean ± s.e.m.; n= 17 and 12
PBS treated pdgfrβcre-;fakfl/fl and pdgfrβcre+;fakfl/fl rings respectively, and 21 and 23 Gas6 treated pdgfrβcre-;fakfl/fl and pdgfrβcre+;fakfl/fl aortic
rings respectively; *p= 0.04. Images of Gas6 stimulated microvessels. Scale bar, 100 μm. b Gas6 expression in B16F0 tumours. Chart, mean ± s.e.m; p=
0.06, n= 3 and 4 sections for CasCtrl and GasKO respectively. Scale bar, 50 μm. Tumour size measurements. Chart, mean ± s.e.m., *p= 0.011; n= 11
pdgfrβcre+;fakfl/fl and 13 pdgfrβcre-;fakfl/flmice. c Cytokine array, p-Axl quantitation. Chart, mean ± s.e.m., *p= 0.0467; n= 4 technical repeats. mRNA Axl
levels unchanged. Chart, Axl mRNA, n= 3 biological repeats. d Western blot, p-Axl in Gas6-stimulated pericytes. Densitometry chart, mean ± s.e.m. n= 3
experimental repeats/genotype. *p= 0.0137, **p= 0.0069. e Axl mRNA-depletion. n= 3 experimental repeats. Chart, Axl mRNA fold change. Tumour
growth (mm3): Graph, mean ± s.e.m., **p= 0.0046, ****p < 0.0001; FAK-null;AxlKO PC, n= 8 mice; Cas6 Ctrl; n= 5 mice, WT Ctrl; n= 10 mice. Tumour
blood vessel density: Chart, mean ± s.e.m., **p= 0.0017. n= 28, 32 and 14 fields of view for FAK-null;AxlKO PC, n= 4 mice; Cas6 Ctrl; n= 4 mice, WT Ctrl;
n= 3 mice respectively. Endomucin staining of tumour sections. Scale bar, 50 μm. f Gas6 expression in pericytes. Charts, mean ± s.e.m., Left chart, n= 6
biological repeats/genotype ****p < 0.0001, ***p= 0.0009; Right chart n= 3 biological repeats/genotype. g Pericytes p-Axl immunostaining. Chart, p-Axl
median staining intensity. ****p < 0.0001, two-sided Mann–Whitney U-test, n= 4 stained slides/genotype. Scale bar, 25 μm. (h) Pericyte Gas6. Chart,
mean ± s.e.m., ***p= 0.0001; n= 3 biological repeats/genotype. Tumour growth: Line graph, mean ± s.e.m., **p= 0.0046, ****p < 0.0001. FAK-null;
Gas6KO: n= 14 mice, FAK-null;Cas9: n= 5 mice, WT;Cas9; n= 10 mice. Tumour blood vessel density; Chart, mean ± s.e.m., *p= 0.0179. n= 28, 15 and 15
fields of view for FAK-null;Gas6KO: n= 4 mice, FAK-null;Cas9: n= 3 mice, WT;Cas9; n= 3 mice respectively. Tumour endomucin immunostaining. Scale
bar, 50 μm. i Western blots; Pericyte p-Pyk2/Pyk2 and p-Src/Src. Densitometric ratios, mean ± s.e.m., n= 3 experimental repeats/genotype. *p= 0.047
(FAKKO 0 vs. FAKKO 10), *p= 0.045 (FAKKO 0 vs. FAKKO20). j Gas6 mRNA quantitation. Chart, mean ± s.e.m, n= 3–4 biological repeats for PF271 treated
cells and 6 for untreated cells. ****p < 0.0006 (WT vs. FAKKO), *p= 0.0127 (WT vs. WT+ PF271), *p= 0.0216 (WT+ PF271 vs. FAKKO+ PF271), ***p=
0.0008 (FAKKO vs. FAKKO+ PF271). a–f, h–j two-sided Students t-test; e, h one-way ANOVA; ns not significant. Source data are provided as a
Source data file.
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normalised to perfused blood vessel density stained with PE-PECAM (MEC13.3,
102507, Biolegend, 1:100). For blood vessel perfusion and blood vessel diameter
measurements in tumours see Supplementary Methods.
Design and construction of CRISPR/Cas9-EGFP plasmids. sgRNAs were
designed using the CRISPOR algorithm (http://crispor.tefor.net). sgRNA
sequences targeting Akt1 (Gene ID: 11651; CATTGAGCGCACCTTCCATG),
Gas6 (Gene ID: 14456;B16- CCGCGCCTACCAAGTCTTCG. PC—GTCGTTCT
CGAACACCTCTC), Axl (Gene ID: 26362; TCGAAGCCACACCACCTCAG),
Ccn1/Cyr61 (Gene ID: 16007; CCGACTCCCGGGGCGCACTT) and F3/Tissue
Factor (TF) (Gene ID: 14006; ACAGTGTAGGTATAGTTGGT) were cloned
into the Lenti-CRISPR–EGFP plasmid (Addgene ID: 75159) using BsmBI
enzyme site.
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Transient Neon electroporation. 5.0 × 105 cells were centrifuged at 300×g for
5 min and re-suspended in 100 μl of R1 buffer (Invitrogen). CRISPR/Cas9-EGFP
plasmid DNA (10 μg) were added into the cells and loaded into a 100 μl Neon
electroporation tip (Invitrogen). Electroporations were performed using 1350 mV
for 20 ms with 2 pulse programme for pericytes and 1300 mV for 20 ms with 2
pulse programme for B16F0 on the Neon Electroporator (Invitrogen). After elec-
troporation, cells were rescued in pre-warmed supplemented media and plated
on 0.1% gelatin with collagen and fibronectin-coated plates for 2 days.
Enriched CRISPR/Cas9-KO cells by flow cytometry. Cells were washed with
phosphate-buffered saline (PBS) and harvested with 200 μl of FACS buffer (1%
BSA and 0.5 mM EDTA in PBS) 48h-post transfection. A 488-nm diode laser was
used for the detection of EGFP. In each sample, viable singlet cells were gated via
forward-scatter (FSC) laser and side-scatter (SSC) and EGFP positive cells,
regardless of expression levels, were sorted using a FACS AriaIII flow cytometer
(BD Biosciences) at the Chelsea flow cytometry and light microscopy facility (See
Supplementary Fig. 12 for Gating strategy).
Gas6 ELISA. WT endothelial cell, B16F0 cell and WT and FAKKO pericyte
conditioned medium (CM) was collected and centrifuged to remove cell debris,
prior to short term storage at 4 °C. Gas6 levels were measured in CM using the
Gas6 ELISA (ThermoFisher Scientific) according to the manufacturers’
instructions.
B16 and CRISPR/Cas9-KO cell tumour growth. WT C57/Bl6 mice were given a
single subcutaneous injection into the flank of 1 × 105 B16F0 cells mixed with 8 ×
105 CRISPR/Cas9-KO pericytes. For B16 CRISPR/Cas9-KO experiments, 1 × 106
B16F0 CRISPR/Cas9-KO cells were injected into either pdgfrßcre+;fakfl/fl and
pdgfrßcre-;fakfl/fl mice. Note, FAK-nullCas9 and WTCas9 tumour growth and
blood vessel density controls are identical in Fig 3e, h, Fig 4e and supplementary fig
10 because they were common controls from the same experimental run.
Immunostaining. Five micrometer frozen tumour sections were air-dried for 10
min, washed once in PBS, fixed in acetone for 10 min at −20 °C, washed in PBS
three times and then blocked with 5% normal goat serum for 30 min at room
temperature. After blocking, sections were incubated with primary antibodies
overnight at 4 °C. Primary antibodies used were directed against endomucin
(V.7C7, 1:100), NG2 (AB5320, Millipore, 1:100), α-SMA (A2547, Sigma, 1:100),
Ki67 (ab15580, Abcam, 1:100). Sections were then washed with PBS and incubated
with Alexa-Fluor®-conjugated secondary antibodies (Invitrogen) for 45 min at
room temperature before mounting the slides with Prolong® Gold anti-fade reagent
(Invitrogen). Formaldehyde fixed sections were de-waxed by immersion in xylene
for 5 and 3 min, followed by re-hydration in a gradient of ethanol diluted in
distilled water (100, 90, 70, and 50%) for 5 min in each solution. After washing
once in PBS, antigen retrieval was performed by heating the samples in 10 mM Na
citrate buffer (trisodium citrate diluted in distilled water, pH 6.0) for 20 min in a
microwave. The samples were then incubated for 5 min at room temperature in 3%
hydrogen peroxide diluted in methanol. Endomucin or SV40 (Pab101, sc-147,
Santa Cruz) antibodies, diluted 1:200 in 1% normal goat serum (NGS) and PBS,
were incubated on the tissue sections overnight at 4 °C. After incubation, tissue
sections were washed three times in PBS followed by 1 h incubation at room
temperature with the appropriate secondary biotinylated antibodies (Dako), diluted
1:100 in 1% NGS PBS. After washing with PBS the tissue sections were incubated
with the ABC reagent (PK-6102, Vector) for 30 min, washed again and DAB
substrate (SK-4100, Vector) was added for 5–10 min until sections turned brown.
After washing, the sections were counterstained with Hematoxylin/Eosin, dehy-
drated and mounted in DPX. A Zeiss AxioPlan microscope and AxioVision soft-
ware were used for imaging the slides. For FAK immunostaining (3285, Cell
Signalling, 1:100), after incubation with primary antibody, slides were incubated
with swine anti-rabbit biotin (E0353, DAKO, 1:100) followed by incubation with
streptavidin-HRP (FP1047, TSA Fluorescence Systems) for 30 min then fluorescein
(FP1018, TSA Fluorescence Systems) for 10 min.
For quantification of pericyte coverage, tumour sections were immunostained
with endomucin (1:100) and α-SMA (1:100) and the numbers of endomucin+/α-
SMA+ and endomucin+/α-SMA- blood vessel were counted. From this the % of
endomucin+/α-SMA+ positive blood vessels were calculated.
For PDGFRβ staining and immune cell infiltration staining see Supplementary
Methods.
Ex vivo aortic ring assay. Thoracic aortas were isolated and prepared for culture
as previously described48. Briefly, 0.5 mm thick rings were serum starved for 18 h at
37 °C before being embedded in 1 mg/ml rat tail collagen type I (Millipore) and
cultured in Opti-MEM® (Gibco) supplemented with 2.5% foetal calf serum (FCS)
with either PBS as a control or 100 ng/ml Gas6 (R&D). Sprouting microvessels
were counted as specified in the figure legends. Following fixation in 4% PFA, the
rings were stained with FITC-conjugated BS-1 Lectin (L9381, Sigma, 1:200) then
mounted on slides using ProLong-GoldTM with anti-fade reagent (Invitrogen).
Zeiss AxioPlan microscope and AxioVision software were used for imaging.
Subcutaneous angiogenesis assay. Two autoclaved synthetic sponges (a kind gift
from Daryl Harmon, Caligen Foam Ltd.) of approximately 1 cm2 were implanted
subcutaneously in both flanks of anaesthetised mice. Every two days, sponges were
injected with either 100 µl of PBS alone or 100 µl of PBS containing 10 ng/ml
VEGF, 10 ng/ml PDGF-B or 10 ng/ml PlGF (Peprotech). After 14 days, sponges
were excised and PFA fixed for paraffin embedding. Sections of sponges were
immunostained for endomucin (1:100) to identify blood vessels, and density was
assessed by counting the numbers of endomucin-positive blood vessels/area of
sponge section.
HUVEC bead sprouting assay. 650 HUVECs were seeded in drops of 20 μl of
medium containing 0.25% of methylcellulose (Sigma-Aldrich) and left overnight to
form spheroids by the “hanging drop” method. Next day, the spheroids were
embedded in 1 mg/ml collagen gels, and then stimulated with Optimem + 1% FBS
supplemented with PBS or 100 ng/ml Cyr61. After 24 h, gels were fixed in 2% PFA,
stained with Rhodamine Phalloidin (R415, ThermoFisher, 1:1000) and cumulative
length of all sprouts from each spheroid were quantified.
Primary cell cultures. Primary mouse lung ECs and primary mouse brain peri-
cytes were isolated from pdgfrβcre+;fakfl/fl and pdgfrβcre-;fakfl/fl control mice and
cultured as previously described49,50. For endothelial cells, pdgfrβcre+;fakfl/fl and
pdgfrβcre-;fakfl/fl mouse lungs were minced, collagenase digested (Type I, Gibco),
strained through a 70 μm cell strainer (BD Falcon) and the resulting cell suspension
plated on flasks coated with a mixture of 0.1% gelatin (Sigma), 10 μg/ml fibronectin
(Millipore) and 30μg/ml rat tail collagen (Sigma). Endothelial cells were purified by
a single negative (FCγ-RII/III; Millipore, MABF838) and two positive cell sorts
(ICAM-2; Pharmingen, 553326), using anti-rat IgG-conjugated magnetic beads
Fig. 4 Pericyte FAK deficiency stimulates increased levels of Tissue Factor expression in B16F0 cells. a Cytokine array. Cyr61 quantitation in FAKKO
pericytes. Chart represents mean ± s.e.m. Representative images of Cyr61dots on array. n= 3 biological repeats in duplicate. ***p= 0.0005. This result
was confirmed by western blotting of Cyr61 with the same lysates. Chart represents mean Cyr61 densitometry, n= 2 experimental repeats. bWestern blot.
Cyr61 expression is increased in FAKKO pericytes. Depletion of Axl (FAK-null;AxlKO) abrogated Cyr61 expression. Chart represents mean ± s.e.m., n= 3
biological repeats. *p= 0.0213, **p= 0.009. c Recombinant Cyr61 stimulated endothelial cell spheroid sprouting. Chart represents mean ± s.e.m., ****p <
0.0001. Scale bar, 100 μm. n= 37 PBS treated spheroids and 30 Cyr61 treated spheroids. d Western blot. Cyr61-depletion in FAK-null;Cyr61KO pericytes.
Chart represents mean Cyr61 levels ± s.e.m., *p= 0.0133; n= 3 experimental repeats. e Tumour growth. Line graph represents mean ± s.e.m., **p=
0.0046, ****p < 0.0001. FAK-null;Cyr61KO: n= 7 mice, FAK-null;Cas9: n= 5 mice, WT;Cas9: n= 10 mice. Tumour blood vessel density. Chart represents
mean blood vessel density/mm2 ± s.e.m., ***p= 0.0006. n= 28, 30 and 14 fields of view from 4 FAK-null;Cas9 tumours; n= 4 FAK-null;Cyr61KO tumours,
and n= 3 WTCas9 tumour sections respectively. Scale bar, 50 μm. Immunostaining for endomucin. f Western blot. p-AKT expression in WT and FAKKO
pericytes. Line graph shows mean ± s.e.m., **p= 0.0043; n= 3 experimental repeats. gWestern blot. PI3-kinase inhibitor (GDC-0941) reduced expression
of Cyr61 after stimulation with Gas6 in FAKKO pericytes (10 and 20min). Chart represent mean ± s.e.m Cyr61 levels. **p= 0.0047; n= 3 biological
repeats. h Cytokine array. Tissue factor (TF) quantification. Representative images of dot blots. Chart represents mean ± s.e.m.TF levels, n= 4 biological
repeats. *p= 0.0295. Western blot analysis confirmed increased TF production in B16F0 melanoma cells co-cultured with FAKKO pericytes. i Western
blotting. B16F0 cells had increased expression of TF in response to exogenous Cyr61 (10 μg/ml). Chart represents mean ± s.e.m. n= 3 experimental
repeats. **p= 0.0048. j Western blot. TF expression is reduced after TF depletion in B16F0 cells. Chart represents mean ± s.e.m., n= 3 lysates.
**p= 0.0016. Tumour volume measurements. Chart represents mean ± s.e.m., *p= 0.0453; n= 10 pdgfrβcre+;fakfl/fl and 16 pdgfrβcre-;fakfl/fl mice.
a–d, f, g–j two-sided Students t test. e, j one-way ANOVA; ns not significant. Source data are provided as a Source Data file.
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(Dynal). During preparation of primary endothelial cells, lung fibroblasts were
isolated from the non-endothelial cell population that was generated during the
first positive sort. For all cell types, passaging occurred when cells reached 70%
confluency. Cells were trypsinised, centrifuged, washed with PBS and replated on
pre-coated flasks for endothelial cells and pericytes and non-coated flasks for
fibroblasts. Fibroblasts were cultured in DMEM+ 10% FCS to passage 4, Endo-
thelial cells in MLEC (Ham’s F-12, DMEM (low glucose), 10% FCS, heparin and
endothelial mitogen (Generon) to passage 4–5. Briefly, for pericytes, brains were
removed from mice, minced, digested for 1 h in 0.1% collagenase, centrifuged in
the presence of 22% BSA, and cultured in endothelial cell growth media (pMLEC)
with the medium changed every 3 days. On reaching confluency, cultures were
harvested with trypsin and passaged. During the first two passages, pericyte cul-
tures were grown in pMLEC, and on the third passage they were grown in pericyte
medium (PM; ScienCell Research Laboratories) containing 2% FBS and antibiotics.
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Tissue culture plates for all experiments were coated with a mixture of collagen
(30 µg/ml), gelatin (0.1%) and fibronectin (10 µg/ml). Primary mouse brain peri-
cytes were characterised using the following markers, by FACS: PDGFRβ, CD146,
CD31 (endothelial marker), glial fibrillary acidic protein and Mac1 (fibroblast
markers). Primary mouse lung endothelial cells were stained for CD31 followed by
FACS analysis and immunostained for endomucin and vimentin (expressed by
ECs) and α-sma (fibroblast marker). Primary mouse lung fibroblasts were
immunostained for vimentin (positive marker for fibroblasts), NG2 and endo-
mucin (negative markers for fibroblasts), as previously described51.
Growth factor stimulation and Western blot analysis. WT and FAKKO pericytes
at around 70% confluence were serum starved for 24 h in Optimem then treated
with PDGF-B (30 ng/ml) (Peprotech) or Gas6 (100 ng/ml or 500 ng/ml) (R&D) for
0, 5, 15, 30, and 60 min. ECs at around 80% confluence were serum starved for 24 h
then treated with either VEGF (30 ng/ml) or PlGF (30 ng/ml) (Peprotech) for 0, 5,
15 30, and 60 min. For PI3K inhibitor experiments, after 24 h serum starvation,
1 μM PI3K inhibitor (GDC-0941) was incubated in the culture medium for 24 h
prior to stimulation with Gas6. For both pericytes and ECs, lysates were prepared
in RIPA buffer containing protease and phosphatase inhibitors (Roche). For ana-
lysis of protein levels, cells were subjected to SDS-PAGE and transferred to
nitrocellulose membranes (Amersham Biosciences) for Western blotting. Blots
were probed for phospho- and total PDGFRß (3161, 3169, Cell Signalling, 1:1000),
phospho and total ERK1/2 (9101, 9102, Cell Signalling, 1:1000), phospho-and total
AKT (4685, 9611, Cell Signalling, 1:1000), AKT 1 (2967, Cell Signalling, 1:1000),
phospho- and total SAPK/JNK (9251, 9252, Cell Signalling, 1:1000), phospho- and
total VEGFR2 (9698, 2478, Cell Signalling, 1:1000), phospho-p65 and total p65
(3033, 8242, Cell Signalling, 1:1000), p-Axl (E-AB-34244, Elabscience, 1:5000),
phospho-Tyro3 (PA5-40270, ThermoFisher, 1:2000) and Tyro3 (5585, Cell Sig-
nalling, 1:1000), Cyr61 (ABC102, Millipore, 5 μg/ml), Pyk2 and p-Pyk2 (3090,
3291, Cell Signalling, 1:1000), Src and p-Src (2108, 6943, Cell Signalling, 1:1000),
Tubulin (T5168, Sigma, 1:5000), GAPDH (AB2302, Millipore, 1:5000) and HSC-70
(Santa Cruz, sc-7298, 1:5000-1:10,000). Densitometric readings of band intensities
were obtained using the ImageJTM software (see Supplementary Fig. 13 for
uncropped scans).
p-Axl immunostaining of pericytes. FAK-null;Gas6KO and FAK-null;Cas9 con-
trol pericytes were seeded on glass coverslips for 24 h. Cells were washed with PBS
and fixed with 4 % PFA for 15 min at room temp and washed again. Cells were
permeabilised with 0.4% TritonX-100 in PBS for 15 min at room temp and washed
with PBS, followed by blocking for 20 min (2.5% goat serum+ 1% BSA+ 0.1% PBS-
T). Cells were incubated overnight at 4 °C with p-Axl primary antibody (R&D,
AF2228) diluted 1:100 in blocking solution then washed three times with PBS
followed by incubation with Alexa Fluor goat anti-rabbit 488 (Invitrogen, A32731,
1:500 dilution in blocking solution) for 1 h at room temp. Cells were washed three
times with PBS, once with water and mounted with Prolong Gold + DAPI
(Invitrogen).
Protein arrays. WT and FAKKO pericyte angiogenesis profiles were compared
using the angiogenesis array (ARY015, R&D Biosystems) and phospho-RTK
profiles were compared using the phospho-RTK array (ARY014, R&D Biosystems).
Briefly, cell lysates were prepared as follows: sample buffer was added to the cell
culture, the cells were scraped and transferred into a 1.5 ml Eppendorf tube. After
sonication, samples were adjusted to the array conditions and mixed with a
Detection Antibody Cocktail as indicated by the manufacturer’s instructions.
Lysates were incubated overnight at 4 °C on dot-blot membranes. Membranes were
washed, incubated with streptavidin-HRP for 30 min at RT, washed again and ECL
was applied to the membrane to reveal the dots.
WT or FAKKO pericytes were co-cultured with B16F0 tumour cells at a ratio of
5:1 in pericyte medium. After 24 h, cells were separated by FACS using the
PDGFRβ receptor antibody (NBP1-43349, Novus Biological, 1:100) which is
positive for pericytes but not for B16F0 tumour cells. Once sorted, the cells were
lysed in sample buffer and analysed using the angiogenesis array as described
above. For the phospho-RTK arrays, WT and FAKKO pericytes were then lysed as
described above and analysed using the phospho-RTK array. Densitometric
analysis was performed using ImageJTM software. Briefly, the same row of array
from multiple experiments, at the same exposure time, were combined and
densitometric analysis performed.
Adhesion assay. WT and FAKKO pericyte adhesion properties were measured
using the CytoSelect™ 48-Well Cell Adhesion Assay (CBA-070, Cell Biolabs).
Detached cells (25,000 cells/well) were seeded on each matrix for 45 min, washed
and fixed following the manufacturer’s instructions. Cell Stain solution was applied
and OD measured at 560 nm with a plate reader.
Proliferation assay. WT and FAKKO pericytes were seeded in a 24-well plate and
subjected to images every 6 h using the IncuCyte® ZOOM system (Essen
Bioscience). Confluency was quantified by analysing cell images over time, using
IncuCyte® ZOOM software (Essen Bioscience). Cell confluency was expressed as
the percentage of coverage of the microscopic field of view.
Dunn chamber assay. Random migration was analysed using Dunn Chambers.
Dunn Chambers were stored in 7× detergent, washed in water to remove any wax,
rinsed in distilled water and sterilised in ethanol before use. Chambers were rinsed
in media and both outer and inner wells were filled with OPTI-MEM. WT and
FAKKOpericytes were plated on coated 22 mm glass coverslips and cultured
overnight. The following day cells were washed with PBS and serum starved for 3 h
in serum-free medium (OPTI-MEM I+GlutaMAX, Gibco, Invitrogen, Paisley,
UK). Coverslips were inverted onto the Dunn Chambers leaving a gap in the outer
well and sealed on three sides with hot wax mixture (Vaseline:paraffin:beeswax—
1:1:1). The media was removed from the outer well by capillary action and was
rinsed with OPTI-MEM before filling with pericyte medium. The chamber was
then sealed with wax and mounted on a Zeiss Axio100 inverted microscope.
Images were acquired by phase contrast imaging using a 10× N-Achroplan Phase
contrast objective (NA 0.25). Cell images were collected using a Sensicam (PCO
Cook) CCD camera, taking a frame every 10 min for 16 h using Micro Manager
acquisition software (NIH, open source). Subsequently all the acquired time-lapse
sequences were displayed as an AVI file and cells from the time-lapse sequence
were tracked using ImageJ. Tracking resulted in the generation of a sequence of
position coordinates relating to each cell in each frame, motion analysis was then
performed on these sequences using Wolfram Mathematica 7 software.
RT-qPCR. RNA was extracted from cells using the RNeasy mini kit according to
the manufacturer’s instructions, (Qiagen UK, Manchester, UK). Complementary
DNA (cDNA) synthesis was carried out using the Applied Biosystems High
Capacity cDNA Reverse Transcription (RT) Kit (Fisher Scientific) as per the
manufacturer’s instructions. Five hundred nanogram of mouse cell cDNA was used
for RT-qPCR. RT-qPCR was performed using sample cDNA (FAM-tagged), an
internal control Gapdh (VIC-tagged) and specific TaqMan probes (Axl, Gas6, Fak,
Pdgfrβ). qPCR was carried out using the TaqMan Universal PCR Master Mix (PE
Applied Biosystems, Fisher Scientific) in a 96-well plate. Hundred and sixty
nanogram of cDNA from each sample was amplified using qPCR across 40 cycles.
Target mRNA was normalised to Gapdh, and the expression level of each gene
determined relative to the initial experimental controls using the 2−ΔΔCT method.
Human tissue sections. Formalin fixed paraffin embedded tissue samples from
human melanoma were sectioned, dewaxed, and antigen retrieval carried out in
boiling 10 mM citrate buffer pH 6.0, 5 mm sections were washed three times in
PBS, blocked in 1% normal goat serum (NGS) 0.1% TritonX-100 (TX-100) for 1 h.
Sections were double immunostained for mouse monoclonal anti-alpha-smooth
muscle actin Cy3-conjugated (Sigma-Aldrich, C6198, 1:100) and for FAK (3285,
Cell Signalling, 1:100). Staining was performed as described in the Immunostaining
section. For data analysis, the percentage of FAK and α-SMA-double-positive blood
vessels was calculated as the number of FAK and α-SMA-double-positive blood
vessels over the total number of α-SMA-positive blood vessels. Patient tissue
samples with less than 50% of α -SMA-positive blood vessels with FAK expression
were classified as low number of mural FAK- positive blood vessels.
Fig. 5 High numbers of pericyte FAK-negative blood vessels are associated with enhanced tumour size and progression in human melanoma.
a Representative images of human melanoma showing both pericyte FAK-positive (arrows) and FAK–negative (arrowheads) blood vessels. Scale bar,
40 μm. b Chart represents the range of percentages of blood vessels that are pericyte-FAK negative for individual patients. n= 28 patient samples.
c Tumour blood vessel density is increased in human melanoma where more than 50% of tumour blood vessels are pericyte FAK-negative. Chart
represents mean ± s.e.m., n= 28 clinical samples, *p= 0.048. d Breslow thickness, an indicator of tumour burden is significantly increased in human
melanoma where more than 50 % of tumour blood vessels are mural FAK negative. Chart represents mean Breslow thickness (mm) ± s.e.m., ****p <
0.0001; n= 28 clinical samples. e The incidence of metastasis is significantly increased when more than 50% of tumour blood vessels are PC FAK-
negative. Chart represents incidence of metastasis (%); n= 14 clinical samples. f Schematic diagram of proposed molecular mechanism of FAKKO pericyte
regulation of tumour growth. Loss of pericyte FAK elevates pPyk2-Gas6-Axl-AKT signalling and subsequent Cyr61 expression that enhances angiogenesis.
In parallel, Cyr61 is sufficient to enhance TF expression in tumour cells, thus enhancing tumour growth. c, d Two-sided Students t-test. Source data are
provided as a Source data file.
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Statistical analysis and reproducibility. The statistical significance of differences
among mean values was determined by one-way ANOVA analysis and unpaired
two-sided Students t-test, p < 0.05 was considered statistically significant, unless
otherwise indicated. For tumour growth statistics, non-parametric Mann–Whitney
U rank sum test was performed to compare tumour volumes each day.
Ethical regulations. All procedures were approved by our local animal ethics
committee, Queen Mary University of London, and were executed in accordance
with United Kingdom Home Office regulations.
Human melanoma samples were obtained with signed informed consent from
patients and ethical committee approval. Melanoma samples were covered by East
London and City Health Authority Ethical Approval (07/Q0604/23 MM: East
London and City Health Authority: “Molecular mechanisms in the pathogenesis of
malignant melanoma”), with a minor amendment in March 2018: ReDa 005044Q1.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All the relevant data that support the findings of this study are available from the
corresponding author on request. Source data are provided with this paper.
Received: 20 July 2018; Accepted: 14 May 2020;
References
1. Armulik, A., Genove, G. & Betsholtz, C. Pericytes: developmental,
physiological, and pathological perspectives, problems, and promises. Dev. Cell
21, 193–215 (2011).
2. Bergers, G. & Song, S. The role of pericytes in blood-vessel formation and
maintenance. Neuro Oncol. 7, 452–464 (2005).
3. Geevarghese, A. & Herman, I. M. Pericyte-endothelial crosstalk: implications
and opportunities for advanced cellular therapies. Transl. Res. 163, 296–306
(2014).
4. Morikawa, S. et al. Abnormalities in pericytes on blood vessels and endothelial
sprouts in tumors. Am. J. Pathol. 160, 985–1000 (2002).
5. De Bock, K., Cauwenberghs, S. & Carmeliet, P. Vessel abnormalization:
another hallmark of cancer? Molecular mechanisms and therapeutic
implications. Curr. Opin. Genet. Dev. 21, 73–79 (2011).
6. Rupp, C. et al. IGFBP7, a novel tumor stroma marker, with growth-promoting
effects in colon cancer through a paracrine tumor-stroma interaction.
Oncogene 34, 815–825 (2015).
7. Luga, V. et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP
signaling in breast cancer cell migration. Cell 151, 1542–1556 (2012).
8. Caspani, E. M., Crossley, P. H., Redondo-Garcia, C. & Martinez, S.
Glioblastoma: a pathogenic crosstalk between tumor cells and pericytes. PLoS
ONE 9, e101402 (2014).
9. Bose, A. et al. Tumor-derived vascular pericytes anergize Th cells. J. Immunol.
191, 971–981 (2013).
10. Sulzmaier, F. J., Jean, C. & Schlaepfer, D. D. FAK in cancer: mechanistic
findings and clinical applications. Nat. Rev. Cancer 14, 598–610 (2014).
11. Lechertier, T. & Hodivala-Dilke, K. Focal adhesion kinase and tumour
angiogenesis. J. Pathol. 226, 404–412 (2012).
12. Braren, R. et al. Endothelial FAK is essential for vascular network stability, cell
survival, and lamellipodial formation. J. Cell Biol. 172, 151–162 (2006).
13. Shen, T. L. et al. Conditional knockout of focal adhesion kinase in endothelial
cells reveals its role in angiogenesis and vascular development in late
embryogenesis. J. Cell Biol. 169, 941–952 (2005).
14. Schlaepfer, D. D., Mitra, S. K. & Ilic, D. Control of motile and invasive cell
phenotypes by focal adhesion kinase. Biochim. Biophys. Acta 1692, 77–102
(2004).
15. Lee, J., Borboa, A. K., Chun, H. B., Baird, A. & Eliceiri, B. P. Conditional
deletion of the focal adhesion kinase FAK alters remodeling of the blood-brain
barrier in glioma. Cancer Res. 70, 10131–10140 (2010).
16. Tavora, B. et al. Endothelial FAK is required for tumour angiogenesis. EMBO
Mol. Med 2, 516–528 (2010).
17. Hanahan, D. Heritable formation of pancreatic beta-cell tumours in
transgenic mice expressing recombinant insulin/simian virus 40 oncogenes.
Nature 315, 115–122 (1985).
18. Hellstrom, M. et al. Lack of pericytes leads to endothelial hyperplasia and
abnormal vascular morphogenesis. J. Cell Biol. 153, 543–553 (2001).
19. Stratman, A. N. & Davis, G. E. Endothelial cell-pericyte interactions stimulate
basement membrane matrix assembly: influence on vascular tube remodeling,
maturation, and stabilization. Microsc. Microanal. 18, 68–80 (2012).
20. Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression
and metastasis. Cell 141, 39–51 (2010).
21. Gustafsson, A., Bostrom, A. K., Ljungberg, B., Axelson, H. & Dahlback, B.
Gas6 and the receptor tyrosine kinase Axl in clear cell renal cell carcinoma.
PLoS ONE 4, e7575 (2009).
22. Kanzaki, R. et al. Gas6 derived from cancer-associated fibroblasts promotes
migration of Axl-expressing lung cancer cells during chemotherapy. Sci. Rep.
7, 10613 (2017).
23. Lemke, G. & Rothlin, C. V. Immunobiology of the TAM receptors. Nat. Rev.
Immunol. 8, 327–336 (2008).
24. Collett, G. et al. Receptor tyrosine kinase Axl modulates the osteogenic
differentiation of pericytes. Circ. Res. 92, 1123–1129 (2003).
25. Sieg, D. J. et al. Pyk2 and Src-family protein-tyrosine kinases compensate for
the loss of FAK in fibronectin-stimulated signaling events but Pyk2 does not
fully function to enhance FAK- cell migration. EMBO J. 17, 5933–5947 (1998).
26. Penzes, K. et al. Combined inhibition of AXL, Lyn and p130Cas kinases block
migration of triple negative breast cancer cells. Cancer Biol. Ther. 15,
1571–1582 (2014).
27. Jun, J. I. & Lau, L. F. Taking aim at the extracellular matrix: CCN proteins as
emerging therapeutic targets. Nat. Rev. Drug Discov. 10, 945–963 (2011).
28. Leu, S. J., Lam, S. C. & Lau, L. F. Pro-angiogenic activities of CYR61 (CCN1)
mediated through integrins alphavbeta3 and alpha6beta1 in human umbilical
vein endothelial cells. J. Biol. Chem. 277, 46248–46255 (2002).
29. Fataccioli, V. et al. Stimulation of angiogenesis by Cyr61 gene: a new
therapeutic candidate. Hum. Gene Ther. 13, 1461–1470 (2002).
30. D’Antonio, K. B. et al. Extracellular matrix associated protein CYR61 is linked
to prostate cancer development. J. Urol. 183, 1604–1610 (2010).
31. Schlegel, J. et al. MERTK receptor tyrosine kinase is a therapeutic target in
melanoma. J. Clin. Invest. 123, 2257–2267 (2013).
32. Axelrod, H. & Pienta, K. J. Axl as a mediator of cellular growth and survival.
Oncotarget 5, 8818–8852 (2014).
33. Xie, D. et al. Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and
associated with more advanced disease. J. Biol. Chem. 276, 14187–14194
(2001).
34. Gery, S. et al. Ovarian carcinomas: CCN genes are aberrantly expressed and
CCN1 promotes proliferation of these cells. Clin. Cancer Res. 11, 7243–7254
(2005).
35. Tsai, M. S., Hornby, A. E., Lakins, J. & Lupu, R. Expression and function of
CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies.
Cancer Res. 60, 5603–5607 (2000).
36. Ruf, W., Yokota, N. & Schaffner, F. Tissue factor in cancer progression and
angiogenesis. Thromb. Res. 125, S36–S38 (2010).
37. Baker, E. A., Leaper, D. J., Hayter, J. P. & Dickenson, A. J. Plasminogen
activator system in oral squamous cell carcinoma. Br. J. Oral Maxillofac. Surg.
45, 623–627 (2007).
38. Dano, K. et al. Plasminogen activation and cancer. Thromb. Haemost. 93,
676–681 (2005).
39. Chen, X. L. et al. VEGF-induced vascular permeability is mediated by FAK.
Dev. Cell 22, 146–157 (2012).
40. Jean, C. et al. Inhibition of endothelial FAK activity prevents tumor metastasis
by enhancing barrier function. J. Cell Biol. 204, 247–263 (2014).
41. Raza, A., Franklin, M. J. & Dudek, A. Z. Pericytes and vessel maturation
during tumor angiogenesis and metastasis. Am. J. Hematol. 85, 593–598
(2010).
42. Song, X. et al. Overexpression of receptor tyrosine kinase Axl promotes tumor
cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer 117,
734–743 (2011).
43. van Ginkel, P. R. et al. Expression of the receptor tyrosine kinase Axl promotes
ocular melanoma cell survival. Cancer Res. 64, 128–134 (2004).
44. Gothert, J. R. et al. Genetically tagging endothelial cells in vivo: bone marrow-
derived cells do not contribute to tumor endothelium. Blood 104, 1769–1777
(2004).
45. Liu, H. et al. Cysteine-rich protein 61 and connective tissue growth factor
induce deadhesion and anoikis of retinal pericytes. Endocrinology 149,
1666–1677 (2008).
46. Sun, Z. J. et al. Involvement of Cyr61 in growth, migration, and metastasis of
prostate cancer cells. Br. J. Cancer 99, 1656–1667 (2008).
47. Abe, K. et al. Regulation of vascular endothelial growth factor production and
angiogenesis by the cytoplasmic tail of tissue factor. Proc. Natl Acad. Sci. USA
96, 8663–8668 (1999).
48. Baker, M. et al. Use of the mouse aortic ring assay to study angiogenesis. Nat.
Protoc. 7, 89–104 (2012).
49. Reynolds, L. E. & Hodivala-Dilke, K. M. Primary mouse endothelial
cell culture for assays of angiogenesis. Methods Mol. Med. 120, 503–509
(2006).
50. Tigges, U., Welser-Alves, J. V., Boroujerdi, A. & Milner, R. A novel and simple
method for culturing pericytes from mouse brain. Microvasc. Res. 84, 74–80
(2012).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16618-6 ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:2810 | https://doi.org/10.1038/s41467-020-16618-6 |www.nature.com/naturecommunications 13
51. Reynolds, L. E. et al. Dual role of pericyte alpha6beta1-integrin in tumour
blood vessels. J. Cell Sci. 130, 1583–1595 (2017).
Acknowledgements
We would like to thank Julie Holdsworth and Bruce Williams from Barts Cancer
Institute (QMUL, UK) for their technical assistance and Professor Ralf Adams (Max
Planck Institute for Molecular Biomedicine, Münster, Germany) for the kind gift of the
pdgfrβcre mice. N.C.H. is supported by a Wellcome Trust Senior Research Fellowship in
Clinical Science (ref. 103749). This work was supported by a Cancer Research UK grant
(C82181/A12007).
Author contributions
T.L. and L.E.R. designed and executed the experiments and wrote the paper. A.R.P. imaged
human melanoma tissue. J.E. did the bead assay and immunostaining quantitation. J.M.-F.
stained and quantified mouse skin tissue section. S.B. did the CD45 staining and quanti-
tation in RIP-Tag mice. F.D. did the SV40 staining. M.P. performed the Dunn chamber
assays. M.D. analysed array data. H.K. and P.M. generated the CrisprCas knockout cells.
P.-P.W. performed immune cell staining. K.P.M. and N.C.H. provided the TdTom;
pdgfrbcre- and TdTom;prdgfrbcr+ unchallenged skin tissue. G.D.-A. helped with western
blots and primary endothelial cell isolation. C.H. provided the human melanoma sections.
K.M.H.-D. supervised the project and wrote the paper.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41467-
020-16618-6.
Correspondence and requests for materials should be addressed to K.M.H.-D.
Peer review information Nature Communications thanks the anonymous reviewer(s) for
their contribution to the peer review of this work.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2020
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-16618-6
14 NATURE COMMUNICATIONS |         (2020) 11:2810 | https://doi.org/10.1038/s41467-020-16618-6 | www.nature.com/naturecommunications
